The Carlsbad, California-based molecular diagnostics firms reported $18.4 million in revenues, up from 14.9 million in Q2 of 2018.
It placed 39 net new ePlex analyzers, expanding the global installed base to 393 placements and growing its installed base by 72 percent compared to the prior-year period.
The company said it expects revenues from its ePlex analyzers to go up approximately 110 percent year over year for Q4.
The company expects to miss the consensus Wall Street revenue estimates for Q4 and full-year 2018.
The company is developing a new gold standard comparator test after it encountered problems with typical culture methods it used in developing a new pneumonia assay.
The company is in discussions with the FDA about a new test being developed for severe bacterial pneumonia and expects to start a clinical trial in Q1 2019.